Last10K.com

Oncobiologics, Inc. (ONS) SEC Filing 10-Q Quarterly report for the period ending Saturday, December 31, 2016

Oncobiologics, Inc.

CIK: 1649989 Ticker: ONS
Document And Entity Information - shares
3 Months Ended
Dec. 31, 2016
Feb. 10, 2017
Document And Entity Information [Abstract]  
Entity Registrant NameOncobiologics, Inc. 
Entity Central Index Key0001649989 
Trading Symbolons 
Current Fiscal Year End Date--09-30 
Entity Filer CategorySmaller Reporting Company 
Entity Common Stock, Shares Outstanding 23,631,448
Document Type10-Q 
Document Period End DateDec. 31, 2016 
Amendment Flagfalse 
Document Fiscal Year Focus2017 
Document Fiscal Period FocusQ1 

View differences made from one quarter to another to evaluate Oncobiologics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncobiologics, Inc..

Continue

Assess how Oncobiologics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncobiologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statement Of Stockholders' Equity (deficit)
Consolidated Statements Of Cash Flows (unaudited)
Consolidated Statements Of Operations (unaudited)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals)
Basis Of Presentation And Summary Of Significant Accounting Policies (details)
Basis Of Presentation And Summary Of Significant Accounting Policies (policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (tables)
Common Stock Warrants
Common Stock Warrants (details)
Common Stock Warrants (tables)
Fair Value Measurements
Fair Value Measurements (details 1)
Fair Value Measurements (details 2)
Fair Value Measurements (details)
Fair Value Measurements (tables)
Liquidity
Liquidity (detail Textuals)
Organization And Description Of Business
Organization And Description Of Business (detail Textuals)
Property And Equipment
Property And Equipment (detail Textuals)
Property And Equipment (details)
Property And Equipment (tables)
Senior Secured Notes
Senior Secured Notes (detail Textuals)
Senior Secured Notes (details)
Senior Secured Notes (tables)
Stock Based Compensation (detail Textuals 1)
Stock Based Compensation (detail Textuals 2)
Stock Based Compensation (detail Textuals 3)
Stock Based Compensation (detail Textuals)
Stock Based Compensation (details 1)
Stock Based Compensation (details 2)
Stock Based Compensation (details 3)
Stock Based Compensation (details)
Stock-based Compensation
Stock-based Compensation (tables)
Subsequent Events
Subsequent Events (detail Textuals)

Material Contracts, Statements, Certifications & more

Oncobiologics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ONS
CIK: 1649989
Form Type: 10-Q Quarterly Report
Accession Number: 0001571049-17-001358
Submitted to the SEC: Tue Feb 14 2017 4:16:49 PM EST
Accepted by the SEC: Tue Feb 14 2017
Period: Saturday, December 31, 2016
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ons/0001571049-17-001358.htm